Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (261-270 of 426) with videos related to

Pageof 43
Sort By:
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid MalignanciesDejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
European Urology|March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.
Cytometry. Part B, Clinical Cytometry|February 22, 2011
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan, Stefan Sleijfer, Michiel H Strijbos, et al.
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Pageof 43

Showing results (261-270 of 426) with videos related to

Sort By:
Pageof 43
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid MalignanciesDejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
European Urology|March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.
Cytometry. Part B, Clinical Cytometry|February 22, 2011
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan, Stefan Sleijfer, Michiel H Strijbos, et al.
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Pageof 43